GlassScriptPhysician profile
Arlene R Sullivan
NPI 1205850542
$5,379.05
in general payments reported to CMS, 2019-2025
12 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 92% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $840 · 2022: $698 · 2023: $1,190 · 2024: $1,166 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,731 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,730.55 |
| Education | $109.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $2,384.72 | 2021-2025 | |
| Harmony Biosciences LLC | $914.01 | 2021-2025 | Wakix |
| Axsome Therapeutics, INC. | $870.32 | 2023-2025 | Sunosi |
| Inspire Medical Systems, INC. | $338.67 | 2022-2025 | Inspire |
| Merck Sharp & Dohme LLC | $209.11 | 2021-2023 | Belsomra |
| Avadel Cns Pharmaceuticals, LLC | $196.00 | 2024-2025 | Lumryz |
| Fisher & Paykel Healthcare INC | $156.15 | 2021-2025 | Fisher & Paykel Healthcare |
| Idorsia Pharmaceuticals US INC | $150.92 | 2022-2023 | Quviviq |
| Eisai INC. | $55.39 | 2021 | |
| Zoll Respicardia, INC. | $39.19 | 2023 | Remede System |
| Lilly USA, LLC | $33.93 | 2025 | Zepbound |
| Resmed Corp | $30.64 | 2022-2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arlene Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.